How to Get GLP-1 Without Insurance: Every Affordable Option (2026)

Last updated: June 9, 2026 · By GLP-1 Cost Finder Team

If you're shopping for a GLP-1 medication without insurance, you've probably already seen the retail prices: Ozempic at roughly $968/month, Wegovy at $1,349/month, Zepbound around $1,060/month. Those numbers are real — they're the manufacturer's list price (WAC) at standard U.S. retail pharmacies — and they're also not what most cash-pay patients actually end up paying.

In 2026 the gap between sticker price and real-world cost is wider than it's ever been. Compounded GLP-1s through licensed telehealth providers start at $133/month all-in. Manufacturer Patient Assistance Programs give qualifying uninsured patients brand-name medication at no cost. Eli Lilly and Novo Nordisk run direct-to-consumer self-pay channels that cut out the pharmacy markup. And for Medicare beneficiaries, the new GLP-1 Bridge Program sets a flat $50/month copay through December 2027.

This is the complete picture — every realistic cash-pay path for every brand-name GLP-1 and every compounded alternative, with current 2026 pricing and the specific situations where each option wins. The shortest version: if you came here expecting $1,000/month, you almost certainly don't have to pay anywhere near that.

The Real Cost of GLP-1s Without Insurance

First, the retail prices — the numbers people are scared of, and the prices almost nobody actually pays:

• Ozempic — approximately $900–$1,100/month retail at most U.S. pharmacies.
• Wegovy — approximately $1,300–$1,400/month retail.
• Mounjaro — approximately $1,000–$1,100/month retail.
• Zepbound — approximately $1,000–$1,100/month retail.
• Foundayo (oral tirzepatide, launched 2026) — varies by dose, with introductory pricing.

The retail price is what walking into Walgreens with no coverage and no savings card costs you. From there, every legitimate path drops your number, and most drop it substantially. The rest of this guide ranks those paths from cheapest to most expensive, with the situations where each makes sense.

1. Compounded GLP-1s Through Telehealth (Lowest Cost Option)

What compounded GLP-1s are

Compounded semaglutide and compounded tirzepatide contain the same active ingredients as the brand-name versions (Wegovy, Ozempic, Zepbound, Mounjaro). The difference is who prepares them. Brand-name versions come from Novo Nordisk or Eli Lilly directly; compounded versions are prepared by licensed compounding pharmacies — either 503A pharmacies (state-licensed, per-prescription) or 503B outsourcing facilities (FDA-registered, batch-produced).

Both compounding categories are regulated. 503A facilities follow USP <797> sterile compounding standards under state pharmacy board oversight. 503B facilities follow Current Good Manufacturing Practice (CGMP) standards under FDA oversight — effectively pharmaceutical-grade production at smaller scale than the brand manufacturers. Both require a prescription from a licensed clinician.

The legal landscape evolved in 2024–2026 as tirzepatide (December 2024) and semaglutide (February 2025) came off the FDA national drug shortage list. Post-shortage, 503A pharmacies can still compound for individual patients with documented medical need. The bulk 503B path is in regulatory transition — the FDA proposed removing GLP-1s from the 503B bulks list in April 2026, with the comment period running through end of June 2026. Per-prescription compounding through licensed providers continues.

Why compounded is cheaper

Two reasons. First, no brand-name pharmaceutical markup — the compounding pharmacy is paid for the formulation work, not for years of marketing budget and patent rents. Second, the competitive telehealth market has been pushing prices steadily down. New entrants (Liv Body, FeelGood) launched in 2026 with transparent all-in pricing that forced earlier providers to clarify their fee structures.

Current 2026 pricing

• Oak — compounded semaglutide at $133/month flat, compounded tirzepatide at $199/month flat. No membership fee, no consultation fee, no shipping fee. Same price at every dose, every month.
• FeelGood — compounded injections from $149/month, compounded tablets from $249/month. HSA/FSA approved. Money-back guarantee. Not available in Louisiana or North Dakota for compounded medications.
• Liv Body — compounded semaglutide $179/month, tirzepatide $279/month. All-in with Care Coach health-coaching layer included.
• Wellorithm, SHED, Sprout Health, Yucca Health — compounded ranges from roughly $147–$385/month depending on medication, dose, and intro pricing.

For the deep dive on how compounded GLP-1s compare to brand-name versions clinically, see our compounded semaglutide vs brand Wegovy guide. Before signing up with any telehealth provider, work through our provider legitimacy checker to verify the platform — the FDA has issued warnings about gray-market sellers that look superficially similar to licensed telehealth.

2. Manufacturer Patient Assistance Programs (Free for Income-Qualified)

If you're uninsured (or your plan doesn't cover the specific medication) and your household income is at or below 400% of federal poverty level — roughly $62,400/year for a single person, $128,600/year for a family of four in 2026 — you may qualify for free brand-name medication through one of two programs:

• NovoCare Patient Assistance Program (Novo Nordisk) provides Ozempic and Wegovy at no cost for qualifying patients. The program accepts Medicare and Medicaid beneficiaries (unlike the Ozempic/Wegovy savings cards). Apply at novocare.com with your prescriber's help. Approval takes 4–8 weeks; medication ships to your prescriber's office.
• Lilly Cares Foundation provides Zepbound at no cost for qualifying patients. Apply at lillycares.com. Same general criteria as NovoCare. Note: Mounjaro is NOT on Lilly Cares' covered list — if you need tirzepatide via Lilly Cares, your prescriber should consider Zepbound instead.

This is the only cash-pay path that gets you brand-name GLP-1s at literally zero cost. The catch is the income limit and the 4–8 week approval window. If you qualify and can wait, this is the cheapest option in the entire guide. If you don't qualify, the compounded telehealth path is the next cheapest.

Full details on every manufacturer cost-help program — including the commercial-insurance savings cards that drop covered copays to $25/month — in our GLP-1 savings cards and patient assistance programs guide.

3. Brand-Name GLP-1s at Reduced Cash-Pay Prices

If you specifically want brand-name medication (and don't qualify for the PAP path), three manufacturer-direct cash channels significantly undercut retail pharmacy pricing.

LillyDirect (Zepbound, Foundayo, Mounjaro)

Eli Lilly's direct-to-consumer pharmacy ships Zepbound KwikPen at $299/month for the 2.5 mg starter dose, $399/month for 5 mg, and $449/month for 7.5 mg and higher. Foundayo (oral tirzepatide) starts at $149/month for the lowest doses through an introductory offer. Mounjaro pricing is configured via the online tool by dose and insurance status. Free delivery. No insurance required.

NovoCare self-pay (Wegovy, Ozempic)

Novo Nordisk's self-pay channel offers Wegovy injection at meaningfully reduced prices versus retail. Pricing varies by dose. The Wegovy tablet (oral semaglutide for weight loss, FDA-approved January 2026) starts at $149/month for the lowest doses through Novo Nordisk's introductory offer.

Brand-specific deep dives

• Wegovy: Every Wegovy cash-pay pathway ranked by monthly cost in cheapest Wegovy without insurance.
• Ozempic: Six cash-pay paths for uninsured Ozempic shoppers in Ozempic cost without insurance.
• Zepbound: LillyDirect, savings card math, and compounded tirzepatide alternatives in Zepbound cost without insurance.

4. New Oral GLP-1 Options

Two oral weight-loss GLP-1s launched in 2026 and dramatically changed the cash-pay landscape:

• Wegovy tablet (oral semaglutide for weight management) — FDA-approved January 2026 by Novo Nordisk. Must be taken on an empty stomach with no more than 4 oz of water, 30 minutes before eating. Starts at $149/month through Novo Nordisk's introductory offer.
• Foundayo (orforglipron, oral tirzepatide-class) — FDA-approved April 1, 2026 by Eli Lilly. First weight-loss GLP-1 pill with no food or water restrictions. Starts at $149/month through Lilly's introductory offer.

Oral GLP-1s eliminate the injection logistics that many patients find off-putting and often arrive at lower introductory prices than injectables. For the full Wegovy-pill-vs-Foundayo head-to-head, see oral GLP-1 cost comparison.

A common misconception: Rybelsus (oral semaglutide 3/7/14 mg from Novo Nordisk) is FDA-approved for type 2 diabetes only, not weight loss. It's sometimes prescribed off-label for weight loss but insurance rarely covers it for that indication. If you specifically want oral semaglutide for weight management, the Wegovy tablet is the on-label option.

5. Medicare and Medicaid Options

Medicare GLP-1 Bridge Program ($50/month)

Starting July 1, 2026, the Medicare GLP-1 Bridge Program provides Wegovy, Zepbound (KwikPen formulation only), and Foundayo at a flat $50/month copay for qualifying Medicare beneficiaries. The program runs through December 31, 2027. Eligibility requires Part D enrollment plus a BMI threshold (≥ 35, or ≥ 30 with qualifying conditions, or ≥ 27 with specific cardiovascular indications).

Full eligibility criteria, the prior authorization process, and what happens after 2027 in our Medicare GLP-1 Bridge Program 2026 guide. Take the free Medicare Bridge eligibility checker for an instant answer based on your specific situation.

State Medicaid coverage

Medicaid coverage of GLP-1s varies enormously by state. All 50 states cover GLP-1s for type 2 diabetes; only 13 states plus DC cover them for chronic weight management as of 2026. The rest either explicitly exclude weight-loss indications or restrict coverage so tightly that practical access is rare. State-by-state breakdown in our Medicaid GLP-1 coverage by state guide.

6. How to Choose the Best Option for You

A decision framework, in plain language, by situation:

If your priority is lowest monthly cost

Compounded telehealth at $133/month all-in (Oak compounded semaglutide). Nothing legitimate beats it for cash-pay shoppers. Tirzepatide path: Oak at $199/month. Trade-off: compounded products are not FDA-approved the way brand-name versions are, even though they contain the same active ingredient and are prepared by regulated pharmacies.

If you specifically want brand-name medication and qualify for Patient Assistance

NovoCare PAP (Ozempic, Wegovy) or Lilly Cares (Zepbound) — free if you qualify. The income threshold (≤ 400% FPL) is more accessible than most people assume. Worth applying even if you're not sure; the application is free and approval is binary.

If you specifically want brand-name and don't qualify for PAP

LillyDirect for Zepbound at $299/month starter, NovoCare self-pay for Wegovy at variable pricing. Brand-name medication, manufacturer pricing, no insurance involvement. Mid-range cost — more expensive than compounded but cheaper than retail.

If you're on Medicare

The Bridge Program at $50/month, if you qualify. Take the eligibility checker first. If you don't qualify (BMI under 27, no qualifying comorbidity, or your Part D plan hasn't opted in), the compounded telehealth path is your backup — no insurance required at all, no eligibility tests, no prior authorization.

If you want oral medication (not injection)

Foundayo or Wegovy tablet, both at $149/month introductory. Foundayo's no-food-restrictions design is a meaningful practical advantage; Wegovy tablet has greater documented weight loss in trials. Honest framing in our oral GLP-1 comparison.

If your insurance denied coverage

The cash-pay paths above are available immediately. While you work the denial — appealing has a 30–50% success rate when well documented — cash-pay can serve as a bridge so you don't have to delay starting therapy. See our GLP-1 insurance denied appeal guide for the step-by-step.

Quick Reference: All Cash-Pay Paths Ranked by Cost

From cheapest realistic monthly cost to most expensive:

1. NovoCare PAP / Lilly Cares — $0/month if income-qualified. Brand-name medication.
2. Medicare GLP-1 Bridge — $50/month for qualifying Medicare beneficiaries.
3. Oak compounded semaglutide — $133/month flat, no fees.
4. FeelGood compounded injections — $149/month all-in.
5. Wegovy tablet introductory offer — $149/month for lowest doses.
6. Foundayo introductory offer — $149/month for lowest doses.
7. Liv Body compounded semaglutide — $179/month all-in.
8. Oak compounded tirzepatide — $199/month flat.
9. LillyDirect Zepbound (2.5 mg starter) — $299/month.
10. Retail pharmacy Ozempic/Wegovy/Zepbound — $900–$1,400/month. Avoid this if you can.

Need to translate this into your specific situation? Run your insurance, condition, and state through the free comparison tool: